196 related articles for article (PubMed ID: 9556785)
1. Phase II and III clinical trials of toremifene for metastatic breast cancer.
Vogel CL
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):9-13. PubMed ID: 9556785
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant trials of toremifene vs tamoxifen: the European experience.
Holli K
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):23-7. PubMed ID: 9556787
[TBL] [Abstract][Full Text] [Related]
3. Phase III trials of toremifene vs tamoxifen.
Gams R
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):23-8. PubMed ID: 9165503
[TBL] [Abstract][Full Text] [Related]
4. Phase I and II studies of toremifene.
Hamm JT
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):19-22. PubMed ID: 9165502
[TBL] [Abstract][Full Text] [Related]
5. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer.
Gershanovich M; Hayes DF; Ellmén J; Vuorinen J
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):29-36. PubMed ID: 9165504
[TBL] [Abstract][Full Text] [Related]
6. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
Mäenpää JU; Ala-Fossi SL
Drugs Aging; 1997 Oct; 11(4):261-70. PubMed ID: 9342556
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer.
Milla-Santos A; Milla L; Rallo L; Solano V
Breast Cancer Res Treat; 2001 Jan; 65(2):119-24. PubMed ID: 11261827
[TBL] [Abstract][Full Text] [Related]
8. [Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].
Gershanovich ML; Garin AM; Baltinia D; Kurvet A; Kangas L; Ellmen Iu
Vopr Onkol; 1997; 43(6):587-95. PubMed ID: 9479357
[TBL] [Abstract][Full Text] [Related]
9. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group.
Gershanovich M; Garin A; Baltina D; Kurvet A; Kangas L; Ellmén J
Breast Cancer Res Treat; 1997 Sep; 45(3):251-62. PubMed ID: 9386869
[TBL] [Abstract][Full Text] [Related]
10. Reliability of estrogen receptors in predicting response to antiestrogens.
Valavaara R
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):14-8. PubMed ID: 9165501
[TBL] [Abstract][Full Text] [Related]
11. Status of antiestrogen breast cancer prevention trials.
Powles TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
[TBL] [Abstract][Full Text] [Related]
12. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
13. [A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer].
Koyama H; Iesato A; Fukushima Y; Okada T; Watanabe T; Harada M; Ito T; Maeno K; Mochizuki Y; Ito K; Amano J
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1123-6. PubMed ID: 21772095
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
Hayes DF; Van Zyl JA; Hacking A; Goedhals L; Bezwoda WR; Mailliard JA; Jones SE; Vogel CL; Berris RF; Shemano I
J Clin Oncol; 1995 Oct; 13(10):2556-66. PubMed ID: 7595707
[TBL] [Abstract][Full Text] [Related]
15. Evolving role of toremifene in the adjuvant setting.
Holli K
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):48-51. PubMed ID: 9165507
[TBL] [Abstract][Full Text] [Related]
16. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
Pyrhönen S; Ellmén J; Vuorinen J; Gershanovich M; Tominaga T; Kaufmann M; Hayes DF
Breast Cancer Res Treat; 1999 Jul; 56(2):133-43. PubMed ID: 10573106
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
[TBL] [Abstract][Full Text] [Related]
19. The significance of estrogen receptors in tamoxifen and toremifene therapy.
Valavaara R; Kangas L
Ann Clin Res; 1988; 20(5):380-8. PubMed ID: 2975479
[TBL] [Abstract][Full Text] [Related]
20. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
Lewis JD; Chagpar AB; Shaughnessy EA; Nurko J; McMasters K; Edwards MJ
Cancer; 2010 May; 116(10):2307-15. PubMed ID: 20209619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]